首页 > 最新文献

Autoimmune Diseases最新文献

英文 中文
Exploring T cell reactivity to gliadin in young children with newly diagnosed celiac disease. 探索新诊断乳糜泻幼儿对麦胶蛋白的T细胞反应性。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-03-03 DOI: 10.1155/2014/927190
Edwin Liu, Kristen McDaniel, Stephanie Case, Liping Yu, Bernd Gerhartz, Nils Ostermann, Gabriela Fankhauser, Valerie Hungerford, Chao Zou, Marcel Luyten, Katherine J Seidl, Aaron W Michels

Class II major histocompatibility molecules confer disease risk in Celiac disease (CD) by presenting gliadin peptides to CD4 T cells in the small intestine. Deamidation of gliadin peptides by tissue transglutaminase creates immunogenic peptides presented by HLA-DQ2 and DQ8 molecules to activate proinflammatory CD4 T cells. Detecting gliadin specific T cell responses from the peripheral blood has been challenging due to low circulating frequencies and heterogeneity in response to gliadin epitopes. We investigated the peripheral T cell responses to alpha and gamma gliadin epitopes in young children with newly diagnosed and untreated CD. Using peptide/MHC recombinant protein constructs, we are able to robustly stimulate CD4 T cell clones previously derived from intestinal biopsies of CD patients. These recombinant proteins and a panel of α- and γ-gliadin peptides were used to assess T cell responses from the peripheral blood. Proliferation assays using peripheral blood mononuclear cells revealed more CD4 T cell responses to α-gliadin than γ-gliadin peptides with a single deamidated α-gliadin peptide able to identify 60% of CD children. We conclude that it is possible to detect T cell responses without a gluten challenge or in vitro stimulus other than antigen, when measuring proliferative responses.

II类主要组织相容性分子通过将麦胶蛋白肽呈递给小肠中的CD4 T细胞而增加乳糜泻(CD)的疾病风险。组织转谷氨酰胺酶对麦胶蛋白肽进行脱酰胺,产生由HLA-DQ2和DQ8分子呈递的免疫原性肽,激活促炎CD4 T细胞。由于麦胶蛋白表位反应的低循环频率和异质性,检测来自外周血的麦胶蛋白特异性T细胞反应一直具有挑战性。我们研究了新诊断和未经治疗的乳糜泻患儿外周血T细胞对α和γ麦胶蛋白表位的反应。使用肽/MHC重组蛋白构建,我们能够强烈刺激CD4 T细胞克隆,这些克隆先前来自乳糜泻患者的肠道活检。这些重组蛋白和一组α-和γ-麦胶蛋白肽被用来评估外周血中的T细胞反应。外周血单个核细胞的增殖试验显示,CD4 T细胞对α-麦胶蛋白的反应比γ-麦胶蛋白肽更多,单个脱酰胺α-麦胶蛋白肽能够识别60%的CD儿童。我们得出的结论是,在测量增殖反应时,可以在没有麸质挑战或抗原以外的体外刺激的情况下检测T细胞反应。
{"title":"Exploring T cell reactivity to gliadin in young children with newly diagnosed celiac disease.","authors":"Edwin Liu,&nbsp;Kristen McDaniel,&nbsp;Stephanie Case,&nbsp;Liping Yu,&nbsp;Bernd Gerhartz,&nbsp;Nils Ostermann,&nbsp;Gabriela Fankhauser,&nbsp;Valerie Hungerford,&nbsp;Chao Zou,&nbsp;Marcel Luyten,&nbsp;Katherine J Seidl,&nbsp;Aaron W Michels","doi":"10.1155/2014/927190","DOIUrl":"https://doi.org/10.1155/2014/927190","url":null,"abstract":"<p><p>Class II major histocompatibility molecules confer disease risk in Celiac disease (CD) by presenting gliadin peptides to CD4 T cells in the small intestine. Deamidation of gliadin peptides by tissue transglutaminase creates immunogenic peptides presented by HLA-DQ2 and DQ8 molecules to activate proinflammatory CD4 T cells. Detecting gliadin specific T cell responses from the peripheral blood has been challenging due to low circulating frequencies and heterogeneity in response to gliadin epitopes. We investigated the peripheral T cell responses to alpha and gamma gliadin epitopes in young children with newly diagnosed and untreated CD. Using peptide/MHC recombinant protein constructs, we are able to robustly stimulate CD4 T cell clones previously derived from intestinal biopsies of CD patients. These recombinant proteins and a panel of α- and γ-gliadin peptides were used to assess T cell responses from the peripheral blood. Proliferation assays using peripheral blood mononuclear cells revealed more CD4 T cell responses to α-gliadin than γ-gliadin peptides with a single deamidated α-gliadin peptide able to identify 60% of CD children. We conclude that it is possible to detect T cell responses without a gluten challenge or in vitro stimulus other than antigen, when measuring proliferative responses. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"927190"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/927190","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32255328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Aspirin for prevention of preeclampsia in lupus pregnancy. 阿司匹林预防狼疮妊娠子痫前期。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-03-20 DOI: 10.1155/2014/920467
Amelie M Schramm, Megan E B Clowse

Preeclampsia, the onset of hypertension and proteinuria during pregnancy, is a common medical disorder with high maternal and fetal mortality and morbidity. The underlying pathology remains poorly understood and includes inflammation, endothelial dysfunction, and an unbalanced thromboxane A2/prostacyclin ratio. For women with systemic lupus erythematosus (SLE), particularly those with preexisting renal disease or with active lupus, the risk of developing preeclampsia is up to 14% higher than it is among healthy individuals. The mechanism is still unknown and the data for preventing preeclampsia in lupus pregnancies are rare. Modulating the impaired thromboxane A2/prostacyclin ratio by administration of low-dose aspirin appears to be the current best option for the prevention of preeclampsia. After providing an overview of the pathogenesis of preeclampsia, preeclampsia in lupus pregnancies, and previous trials for prevention of preeclampsia with aspirin treatment, we recommend low-dose aspirin administration for all lupus patients starting prior to 16 weeks of gestation. Patients with SLE and antiphospholipid syndrome should receive treatment with heparin and low-dose aspirin during pregnancy.

先兆子痫是妊娠期高血压和蛋白尿的发病,是一种常见的医学疾病,母婴死亡率和发病率高。潜在的病理仍然知之甚少,包括炎症、内皮功能障碍和不平衡的血栓素A2/前列环素比例。对于患有系统性红斑狼疮(SLE)的女性,特别是那些先前存在肾脏疾病或活动性狼疮的女性,发生先兆子痫的风险比健康人高14%。其机制尚不清楚,预防狼疮妊娠子痫前期的数据也很少。通过给药低剂量阿司匹林来调节受损的血栓素A2/前列环素比率似乎是目前预防先兆子痫的最佳选择。在概述了先兆子痫的发病机制,狼疮妊娠的先兆子痫,以及先前用阿司匹林治疗预防先兆子痫的试验后,我们建议所有狼疮患者在妊娠16周之前开始使用低剂量阿司匹林。SLE合并抗磷脂综合征的患者在妊娠期间应接受肝素和小剂量阿司匹林的治疗。
{"title":"Aspirin for prevention of preeclampsia in lupus pregnancy.","authors":"Amelie M Schramm,&nbsp;Megan E B Clowse","doi":"10.1155/2014/920467","DOIUrl":"https://doi.org/10.1155/2014/920467","url":null,"abstract":"<p><p>Preeclampsia, the onset of hypertension and proteinuria during pregnancy, is a common medical disorder with high maternal and fetal mortality and morbidity. The underlying pathology remains poorly understood and includes inflammation, endothelial dysfunction, and an unbalanced thromboxane A2/prostacyclin ratio. For women with systemic lupus erythematosus (SLE), particularly those with preexisting renal disease or with active lupus, the risk of developing preeclampsia is up to 14% higher than it is among healthy individuals. The mechanism is still unknown and the data for preventing preeclampsia in lupus pregnancies are rare. Modulating the impaired thromboxane A2/prostacyclin ratio by administration of low-dose aspirin appears to be the current best option for the prevention of preeclampsia. After providing an overview of the pathogenesis of preeclampsia, preeclampsia in lupus pregnancies, and previous trials for prevention of preeclampsia with aspirin treatment, we recommend low-dose aspirin administration for all lupus patients starting prior to 16 weeks of gestation. Patients with SLE and antiphospholipid syndrome should receive treatment with heparin and low-dose aspirin during pregnancy. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"920467"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/920467","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32300753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 46
Celiac disease in adult patients: specific autoantibodies in the diagnosis, monitoring, and screening. 成人乳糜泻患者:特异性自身抗体在诊断、监测和筛查中的应用
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-04-03 DOI: 10.1155/2014/623514
Evagelia Trigoni, Alexandra Tsirogianni, Elena Pipi, Gerassimos Mantzaris, Chryssa Papasteriades

The increasing prevalence of celiac disease (CD), especially in adults, its atypical clinical presentation, and the strict, lifelong adherence to gluten-free diet (GFD) as the only option for healthy state create an imperative need for noninvasive methods that can effectively diagnose CD and monitor GFD. Aim. Evaluation of anti-endomysium (EmA) and anti-tissue transglutaminase IgA (tTG-A) antibodies in CD diagnosis, GFD monitoring, and first degree relatives screening in CD adult patients. Methods. 70 newly diagnosed Greek adult patients, 70 controls, and 47 first degree relatives were tested for the presence of EmA and tTG-A. The CD patients were monitored during a 3-year period. Results. EmA predictive ability for CD diagnosis was slightly better compared to tTG-A (P = 0.043). EmA could assess compliance with GFD already from the beginning of the diet, while both EmA and tTG-A had an equal ability to discriminate between strictly and partially compliant patients after the first semester and so on. Screening of first degree relatives resulted in the identification of 2 undiagnosed CD cases. Conclusions. Both EmA and tTG-A are suitable markers in the CD diagnosis, in the screening of CD among first degree relatives, having also an equal performance in the long term monitoring.

乳糜泻(CD)患病率的增加,尤其是在成人中,其非典型的临床表现,以及严格的,终身坚持无麸质饮食(GFD)作为健康状态的唯一选择,迫切需要能够有效诊断乳糜泻和监测GFD的无创方法。的目标。评估抗肌内膜(EmA)和抗组织转谷氨酰胺酶IgA (tTG-A)抗体在乳糜泻诊断、GFD监测和乳糜泻成年患者一级亲属筛查中的价值方法:对70例新诊断的希腊成年患者、70例对照组和47例一级亲属进行EmA和tTG-A检测。对乳糜泻患者进行为期3年的监测。结果。EmA对CD诊断的预测能力略高于tTG-A (P = 0.043)。EmA可以从饮食开始就评估对GFD的依从性,而EmA和tTG-A在第一学期后对严格依从和部分依从的患者具有同等的区分能力。一级亲属筛查导致2例未确诊的乳糜泻病例。结论。EmA和tTG-A在乳糜泻诊断和一级亲属乳糜泻筛查中都是合适的标志物,在长期监测中也有相同的表现。
{"title":"Celiac disease in adult patients: specific autoantibodies in the diagnosis, monitoring, and screening.","authors":"Evagelia Trigoni,&nbsp;Alexandra Tsirogianni,&nbsp;Elena Pipi,&nbsp;Gerassimos Mantzaris,&nbsp;Chryssa Papasteriades","doi":"10.1155/2014/623514","DOIUrl":"https://doi.org/10.1155/2014/623514","url":null,"abstract":"<p><p>The increasing prevalence of celiac disease (CD), especially in adults, its atypical clinical presentation, and the strict, lifelong adherence to gluten-free diet (GFD) as the only option for healthy state create an imperative need for noninvasive methods that can effectively diagnose CD and monitor GFD. Aim. Evaluation of anti-endomysium (EmA) and anti-tissue transglutaminase IgA (tTG-A) antibodies in CD diagnosis, GFD monitoring, and first degree relatives screening in CD adult patients. Methods. 70 newly diagnosed Greek adult patients, 70 controls, and 47 first degree relatives were tested for the presence of EmA and tTG-A. The CD patients were monitored during a 3-year period. Results. EmA predictive ability for CD diagnosis was slightly better compared to tTG-A (P = 0.043). EmA could assess compliance with GFD already from the beginning of the diet, while both EmA and tTG-A had an equal ability to discriminate between strictly and partially compliant patients after the first semester and so on. Screening of first degree relatives resulted in the identification of 2 undiagnosed CD cases. Conclusions. Both EmA and tTG-A are suitable markers in the CD diagnosis, in the screening of CD among first degree relatives, having also an equal performance in the long term monitoring. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"623514"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/623514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32322662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Elements of the B cell signalosome are differentially affected by mercury intoxication. 汞中毒对B细胞信号体的影响是不同的。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-05-04 DOI: 10.1155/2014/239358
Randall F Gill, Michael J McCabe, Allen J Rosenspire

It has been suggested that environmental exposures to mercury contribute to autoimmune disease. Disruption of BCR signaling is associated with failure of central tolerance and autoimmunity, and we have previously shown that low levels of Hg(2+) interfere with BCR signaling. In this report we have employed multiparametric phosphoflow cytometry, as well as a novel generalization of the Overton algorithm from one- to two-dimensional unimodal distributions to simultaneously monitor the effect of low level Hg(2+) intoxication on activation of ERK and several upstream elements of the BCR signaling pathway in WEHI-231 B cells. We have found that, after exposure to low levels of Hg(2+), only about a third of the cells are sensitive to the metal. For those cells which are sensitive, we confirm our earlier work that activation of ERK is attenuated but now report that Hg(2+) has little upstream effect on the Btk tyrosine kinase. On the other hand, we find that signaling upstream through the Syk tyrosine kinase is actually augmented, as is upstream activation of the B cell signalosome scaffolding protein BLNK.

有研究表明,环境暴露于汞会导致自身免疫性疾病。BCR信号的破坏与中枢耐受性和自身免疫的失败有关,我们之前已经证明低水平的Hg(2+)干扰BCR信号。在本报告中,我们采用了多参数磷酸流式细胞术,以及从一维到二维单峰分布的Overton算法的新推广,以同时监测低水平汞(2+)中毒对WEHI-231 B细胞中ERK和BCR信号通路上游元件激活的影响。我们发现,在暴露于低水平的汞(2+)之后,只有大约三分之一的细胞对这种金属敏感。对于那些敏感的细胞,我们证实了我们早期的工作,即ERK的激活被减弱,但现在报道Hg(2+)对Btk酪氨酸激酶的上游影响很小。另一方面,我们发现通过Syk酪氨酸激酶的上游信号实际上是增强的,正如B细胞信号小体支架蛋白BLNK的上游激活一样。
{"title":"Elements of the B cell signalosome are differentially affected by mercury intoxication.","authors":"Randall F Gill,&nbsp;Michael J McCabe,&nbsp;Allen J Rosenspire","doi":"10.1155/2014/239358","DOIUrl":"https://doi.org/10.1155/2014/239358","url":null,"abstract":"<p><p>It has been suggested that environmental exposures to mercury contribute to autoimmune disease. Disruption of BCR signaling is associated with failure of central tolerance and autoimmunity, and we have previously shown that low levels of Hg(2+) interfere with BCR signaling. In this report we have employed multiparametric phosphoflow cytometry, as well as a novel generalization of the Overton algorithm from one- to two-dimensional unimodal distributions to simultaneously monitor the effect of low level Hg(2+) intoxication on activation of ERK and several upstream elements of the BCR signaling pathway in WEHI-231 B cells. We have found that, after exposure to low levels of Hg(2+), only about a third of the cells are sensitive to the metal. For those cells which are sensitive, we confirm our earlier work that activation of ERK is attenuated but now report that Hg(2+) has little upstream effect on the Btk tyrosine kinase. On the other hand, we find that signaling upstream through the Syk tyrosine kinase is actually augmented, as is upstream activation of the B cell signalosome scaffolding protein BLNK. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"239358"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/239358","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32379778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Autoimmunity and the gut. 自身免疫和肠道
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-05-13 DOI: 10.1155/2014/152428
Andrew W Campbell

Autoimmune diseases have increased dramatically worldwide since World War II. This is coincidental with the increased production and use of chemicals both in industrial countries and agriculture, as well as the ease of travel from region to region and continent to continent, making the transfer of a pathogen or pathogens from one part of the world to another much easier than ever before. In this review, triggers of autoimmunity are examined, principally environmental. The number of possible environmental triggers is vast and includes chemicals, bacteria, viruses, and molds. Examples of these triggers are given and include the mechanism of action and method by which they bring about autoimmunity.

自第二次世界大战以来,自身免疫性疾病在世界范围内急剧增加。这与工业化国家和农业中化学品的生产和使用增加,以及从一个区域到另一个区域、从一个大陆到另一个大陆旅行的便利性相吻合,使得一种或多种病原体从世界的一个地方转移到另一个地方比以往任何时候都容易得多。在这篇综述中,研究了自身免疫的触发因素,主要是环境。可能的环境诱因有很多,包括化学物质、细菌、病毒和霉菌。给出了这些触发因素的例子,包括它们产生自身免疫的作用机制和方法。
{"title":"Autoimmunity and the gut.","authors":"Andrew W Campbell","doi":"10.1155/2014/152428","DOIUrl":"https://doi.org/10.1155/2014/152428","url":null,"abstract":"<p><p>Autoimmune diseases have increased dramatically worldwide since World War II. This is coincidental with the increased production and use of chemicals both in industrial countries and agriculture, as well as the ease of travel from region to region and continent to continent, making the transfer of a pathogen or pathogens from one part of the world to another much easier than ever before. In this review, triggers of autoimmunity are examined, principally environmental. The number of possible environmental triggers is vast and includes chemicals, bacteria, viruses, and molds. Examples of these triggers are given and include the mechanism of action and method by which they bring about autoimmunity. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"152428"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/152428","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32399254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 62
An update in guillain-barré syndrome. guillain- barr<s:1>综合征的最新进展。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-01-06 DOI: 10.1155/2014/793024
J B Winer

Guillain-Barré syndrome (GBS) was first described in 1916 (Guillain G, 1916) and is approaching its 100th anniversary. Our knowledge of the syndrome has hugely expanded since that time. Once originally considered to be only demyelinating in pathology we now recognise both axonal and demyelinating subtypes. Numerous triggering or antecedent events including infections are recognised and GBS is considered an immunological response to these. GBS is now considered to be a clinical syndrome of an acute inflammatory neuropathy encompassing a number of subtypes with evidence of different immunological mechanisms. Some of these are clearly understood while others remain to be fully elucidated. Complement fixing antibodies against peripheral nerve gangliosides alone and in combination are increasingly recognised as an important mechanism of nerve damage. New antibodies against other nerve antigens such as neurofascin have been recently described. Research databases have been set up to look at factors associated with prognosis and the influence of intravenous immunoglobulin (IvIg) pharmacokinetics in therapy. Exciting new studies are in progress to examine a possible role for complement inhibition in the treatment of the syndrome.

吉兰-巴罗综合征(GBS)于1916年首次被发现(Guillain G, 1916),目前已接近100周年。从那时起,我们对这种综合症的认识得到了极大的扩展。一旦最初被认为只是在病理脱髓鞘,我们现在认识到轴突和脱髓鞘亚型。包括感染在内的许多触发或先行事件已被确认,GBS被认为是对这些事件的免疫反应。GBS现在被认为是一种急性炎症性神经病变的临床综合征,包括许多亚型,有不同免疫机制的证据。其中一些已被清楚地理解,而另一些仍有待充分阐明。针对周围神经神经节苷脂单独或联合的补体固定抗体越来越被认为是神经损伤的重要机制。针对其他神经抗原(如神经束蛋白)的新抗体最近已被描述。研究数据库已经建立,以观察与预后相关的因素和静脉注射免疫球蛋白(IvIg)药代动力学在治疗中的影响。令人兴奋的新研究正在进行中,以检查补体抑制在治疗该综合征中的可能作用。
{"title":"An update in guillain-barré syndrome.","authors":"J B Winer","doi":"10.1155/2014/793024","DOIUrl":"https://doi.org/10.1155/2014/793024","url":null,"abstract":"<p><p>Guillain-Barré syndrome (GBS) was first described in 1916 (Guillain G, 1916) and is approaching its 100th anniversary. Our knowledge of the syndrome has hugely expanded since that time. Once originally considered to be only demyelinating in pathology we now recognise both axonal and demyelinating subtypes. Numerous triggering or antecedent events including infections are recognised and GBS is considered an immunological response to these. GBS is now considered to be a clinical syndrome of an acute inflammatory neuropathy encompassing a number of subtypes with evidence of different immunological mechanisms. Some of these are clearly understood while others remain to be fully elucidated. Complement fixing antibodies against peripheral nerve gangliosides alone and in combination are increasingly recognised as an important mechanism of nerve damage. New antibodies against other nerve antigens such as neurofascin have been recently described. Research databases have been set up to look at factors associated with prognosis and the influence of intravenous immunoglobulin (IvIg) pharmacokinetics in therapy. Exciting new studies are in progress to examine a possible role for complement inhibition in the treatment of the syndrome. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"793024"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/793024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32101941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 72
A comparison of anti-nuclear antibody quantification using automated enzyme immunoassays and immunofluorescence assays. 使用自动酶免疫测定法和免疫荧光测定法测定抗核抗体的比较。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-01-28 DOI: 10.1155/2014/534759
Renata Baronaite, Merete Engelhart, Troels Mørk Hansen, Gorm Thamsborg, Hanne Slott Jensen, Steen Stender, Pal Bela Szecsi

Anti-nuclear antibodies (ANA) have traditionally been evaluated using indirect fluorescence assays (IFA) with HEp-2 cells. Quantitative immunoassays (EIA) have replaced the use of HEp-2 cells in some laboratories. Here, we evaluated ANA in 400 consecutive and unselected routinely referred patients using IFA and automated EIA techniques. The IFA results generated by two independent laboratories were compared with the EIA results from antibodies against double-stranded DNA (dsDNA), from ANA screening, and from tests of the seven included subantigens. The final IFA and EIA results for 386 unique patients were compared. The majority of the results were the same between the two methods (n = 325, 84%); however, 8% (n = 30) yielded equivocal results (equivocal-negative and equivocal-positive) and 8% (n = 31) yielded divergent results (positive-negative). The results showed fairly good agreement, with Cohen's kappa value of 0.30 (95% confidence interval (CI) = 0.14-0.46), which decreased to 0.23 (95% CI = 0.06-0.40) when the results for dsDNA were omitted. The EIA method was less reliable for assessing nuclear and speckled reactivity patterns, whereas the IFA method presented difficulties detecting dsDNA and Ro activity. The automated EIA method was performed in a similar way to the conventional IFA method using HEp-2 cells; thus, automated EIA may be used as a screening test.

抗核抗体(ANA)传统上用间接荧光法(IFA)对HEp-2细胞进行评估。在一些实验室中,定量免疫分析(EIA)已经取代了HEp-2细胞的使用。在这里,我们使用IFA和自动EIA技术评估了400例连续和未选择的常规转诊患者的ANA。由两个独立实验室生成的IFA结果与针对双链DNA (dsDNA)抗体的EIA结果、ANA筛选结果以及7种包括的亚抗原测试结果进行了比较。对386例特殊患者的最终IFA和EIA结果进行比较。两种方法的大部分结果相同(n = 325, 84%);然而,8% (n = 30)产生了模棱两可的结果(模棱两可的阴性和模棱两可的阳性),8% (n = 31)产生了分歧的结果(阳性和阴性)。结果显示出相当好的一致性,Cohen的kappa值为0.30(95%置信区间(CI) = 0.14-0.46),当忽略dsDNA的结果时,Cohen的kappa值降至0.23 (95% CI = 0.06-0.40)。EIA方法在评估核和斑点反应模式方面不太可靠,而IFA方法在检测dsDNA和Ro活性方面存在困难。自动化EIA方法与使用HEp-2细胞的传统IFA方法类似;因此,自动化环评可以用作筛选测试。
{"title":"A comparison of anti-nuclear antibody quantification using automated enzyme immunoassays and immunofluorescence assays.","authors":"Renata Baronaite,&nbsp;Merete Engelhart,&nbsp;Troels Mørk Hansen,&nbsp;Gorm Thamsborg,&nbsp;Hanne Slott Jensen,&nbsp;Steen Stender,&nbsp;Pal Bela Szecsi","doi":"10.1155/2014/534759","DOIUrl":"https://doi.org/10.1155/2014/534759","url":null,"abstract":"<p><p>Anti-nuclear antibodies (ANA) have traditionally been evaluated using indirect fluorescence assays (IFA) with HEp-2 cells. Quantitative immunoassays (EIA) have replaced the use of HEp-2 cells in some laboratories. Here, we evaluated ANA in 400 consecutive and unselected routinely referred patients using IFA and automated EIA techniques. The IFA results generated by two independent laboratories were compared with the EIA results from antibodies against double-stranded DNA (dsDNA), from ANA screening, and from tests of the seven included subantigens. The final IFA and EIA results for 386 unique patients were compared. The majority of the results were the same between the two methods (n = 325, 84%); however, 8% (n = 30) yielded equivocal results (equivocal-negative and equivocal-positive) and 8% (n = 31) yielded divergent results (positive-negative). The results showed fairly good agreement, with Cohen's kappa value of 0.30 (95% confidence interval (CI) = 0.14-0.46), which decreased to 0.23 (95% CI = 0.06-0.40) when the results for dsDNA were omitted. The EIA method was less reliable for assessing nuclear and speckled reactivity patterns, whereas the IFA method presented difficulties detecting dsDNA and Ro activity. The automated EIA method was performed in a similar way to the conventional IFA method using HEp-2 cells; thus, automated EIA may be used as a screening test. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"534759"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/534759","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32174769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Systemic lupus erythematosus 2014. 系统性红斑狼疮2014。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-03-24 DOI: 10.1155/2014/274323
Juan-Manuel Anaya, Yehuda Shoenfeld, Ricard Cervera
Systemic lupus erythematosus (SLE, lupus) is the prototype of systemic autoimmune disease (AD). Immune system activation in SLE is characterized by exaggerated B-cell and T-cell responses and loss of immune tolerance against self-antigens. Production and defective elimination of antibodies, circulation and tissue deposition of immune complexes, and complement and cytokine activation contribute to clinical manifestations that range from fatigue and joint pain to severe, life-threatening organ damage [1]. In this special issue, nine papers were selected covering important topics of the disease from B lymphocytes (e.g., autoantibodies and B-cell depletion therapy), immunosenescence, and genetics to disease complications such as cardiovascular disease (CVD), preeclampsia, fatigue, and depression. B lymphocytes are the effectors of humoral immunity, providing defense from pathogens through different functions including antibody production. In the context of ADs, B lymphocytes play an essential role by not only producing autoantibodies but also functioning as antigen presenting cells and as a source of cytokines as pointed out by G. J. Tobon and colleagues, who reviewed the functions of B lymphocytes in autoimmunity and ADs with a special focus on their abnormalities in SLE. We recognize today that disease manifestations are determined by the diversity of autoantibodies appearing in SLE [2, 3]. This explains the different clinical presentations within individuals with SLE. In this issue, E. Cozzani and colleagues reviewed the most important autoantibodies in SLE and their correlation between immunopathological features and clinical aspects. Recommendations for determining anti-nuclear antibodies, anti-double stranded DNA antibodies, specific antibodies, and validation of methods have been published elsewhere [4]. Given that autoantibody production is the hallmark of SLE, it is not surprising that B-cell depletion therapy is a promising therapeutic option in the management of SLE. Rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, has been used off-license in the management of severe refractory SLE since 2002. In this special issue, F. Bonilla-Abadia and colleagues report the results of a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with RTX as remission induction therapy and maintenance. They observed a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease suggesting that RTX could be effective and safe in patients with SLE refractory to conventional therapy. An important matter about SLE for 2014 will be the progress and even release of results of the ongoing trials with the new biological therapies including epratuzumab, a humanized anti-CD22 monoclonal antibody, and subcutaneous belimumab, a human monoclonal antibody that inhibits B-lymphocyte stimulator, as well as the investigator-in
{"title":"Systemic lupus erythematosus 2014.","authors":"Juan-Manuel Anaya,&nbsp;Yehuda Shoenfeld,&nbsp;Ricard Cervera","doi":"10.1155/2014/274323","DOIUrl":"https://doi.org/10.1155/2014/274323","url":null,"abstract":"Systemic lupus erythematosus (SLE, lupus) is the prototype of systemic autoimmune disease (AD). Immune system activation in SLE is characterized by exaggerated B-cell and T-cell responses and loss of immune tolerance against self-antigens. Production and defective elimination of antibodies, circulation and tissue deposition of immune complexes, and complement and cytokine activation contribute to clinical manifestations that range from fatigue and joint pain to severe, life-threatening organ damage [1]. In this special issue, nine papers were selected covering important topics of the disease from B lymphocytes (e.g., autoantibodies and B-cell depletion therapy), immunosenescence, and genetics to disease complications such as cardiovascular disease (CVD), preeclampsia, fatigue, and depression. B lymphocytes are the effectors of humoral immunity, providing defense from pathogens through different functions including antibody production. In the context of ADs, B lymphocytes play an essential role by not only producing autoantibodies but also functioning as antigen presenting cells and as a source of cytokines as pointed out by G. J. Tobon and colleagues, who reviewed the functions of B lymphocytes in autoimmunity and ADs with a special focus on their abnormalities in SLE. We recognize today that disease manifestations are determined by the diversity of autoantibodies appearing in SLE [2, 3]. This explains the different clinical presentations within individuals with SLE. In this issue, E. Cozzani and colleagues reviewed the most important autoantibodies in SLE and their correlation between immunopathological features and clinical aspects. Recommendations for determining anti-nuclear antibodies, anti-double stranded DNA antibodies, specific antibodies, and validation of methods have been published elsewhere [4]. Given that autoantibody production is the hallmark of SLE, it is not surprising that B-cell depletion therapy is a promising therapeutic option in the management of SLE. Rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, has been used off-license in the management of severe refractory SLE since 2002. In this special issue, F. Bonilla-Abadia and colleagues report the results of a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with RTX as remission induction therapy and maintenance. They observed a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease suggesting that RTX could be effective and safe in patients with SLE refractory to conventional therapy. An important matter about SLE for 2014 will be the progress and even release of results of the ongoing trials with the new biological therapies including epratuzumab, a humanized anti-CD22 monoclonal antibody, and subcutaneous belimumab, a human monoclonal antibody that inhibits B-lymphocyte stimulator, as well as the investigator-in","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"274323"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/274323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32303184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Advances in neuroimmunology: from bench to bedside. 神经免疫学的进展:从实验到临床。
IF 4 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-01-19 DOI: 10.1155/2014/812847
Cristoforo Comi, Umberto Dianzani, Filippo Martinelli Boneschi, Daniel L Menkes
The understanding of the interactions between the immune and the nervous systems and the resultant therapeutic implications has expanded significantly in the last decade [1]. There have been significant developments in the field of neuroimmunology as new antibody-mediated disorders have been described and involvement of the immune system in the pathogenesis of neurodegenerative diseases has been established [2, 3]. These discoveries have led to novel and effective treatments, which have broadened our therapeutic options regarding neuroimmune disorders [4, 5]. The goal of this special issue was to address the translational aspects of neuroimmunology, “from bench to bedside,” in order to update clinicians on basic research discoveries that will have therapeutic clinical efficacy. Moreover, there was an emphasis on conditions that have undergone a systematic nosographic characterization which have resulted in therapeutic approaches with greater specificity. In this context, the paper entitled “Immunotherapy of neuromyelitis optica” provides a framework for understanding an antibody-mediated central nervous system demyelinating disease that has a different pathophysiology than multiple sclerosis (MS). This distinction is important as NMO responds to different immunomodulating agents than does MS. The spectrum of pediatric MS has also been the focus of extensive nosographic revision in recent years, and diagnostic criteria have been recently revised by the International Pediatric Multiple Sclerosis Study Group (IPMSSG) [6]. The paper “Pediatric multiple sclerosis: current concepts and consensus definitions” offers a careful update on risk factors, clinical manifestations, diagnostic procedures, prognostic implications, and treatment of this increasingly frequent form of MS. MS is a salient neuroimmunological disease for which the “bench to bedside approach” has provided the greatest therapeutic advances. Although there are more treatments for MS, the study of novel and less explored molecular pathways ought to provide relevant alternative targets. This concept is well expressed in the paper entitled “Current understanding on the role of standard- and immuno-proteasomes in inflammatory/immunological pathways of Multiple Sclerosis,” in which the authors describe the current knowledge on the potential role of proteasomes in MS and discuss the pro et contra of possible therapies for MS targeting proteasome isoforms. Immune mediated diseases of the peripheral nervous system (PNS) are less studied than their “central” counterparts [7]. Nonetheless, important advances in both pathogenesis and treatment of inflammatory demyelinating neuropathies have been extensively evaluated in the articles authored by J. B. Weiner and P. Ripellino et al. The first publication entitled “An update in Guillain-Barre Syndrome” provides a comprehensive discussion of the current state of knowledge on acute inflammatory neuropathies from diagnosis to treatment. The se
{"title":"Advances in neuroimmunology: from bench to bedside.","authors":"Cristoforo Comi,&nbsp;Umberto Dianzani,&nbsp;Filippo Martinelli Boneschi,&nbsp;Daniel L Menkes","doi":"10.1155/2014/812847","DOIUrl":"https://doi.org/10.1155/2014/812847","url":null,"abstract":"The understanding of the interactions between the immune and the nervous systems and the resultant therapeutic implications has expanded significantly in the last decade [1]. There have been significant developments in the field of neuroimmunology as new antibody-mediated disorders have been described and involvement of the immune system in the pathogenesis of neurodegenerative diseases has been established [2, 3]. These discoveries have led to novel and effective treatments, which have broadened our therapeutic options regarding neuroimmune disorders [4, 5]. \u0000 \u0000The goal of this special issue was to address the translational aspects of neuroimmunology, “from bench to bedside,” in order to update clinicians on basic research discoveries that will have therapeutic clinical efficacy. Moreover, there was an emphasis on conditions that have undergone a systematic nosographic characterization which have resulted in therapeutic approaches with greater specificity. In this context, the paper entitled “Immunotherapy of neuromyelitis optica” provides a framework for understanding an antibody-mediated central nervous system demyelinating disease that has a different pathophysiology than multiple sclerosis (MS). This distinction is important as NMO responds to different immunomodulating agents than does MS. \u0000 \u0000The spectrum of pediatric MS has also been the focus of extensive nosographic revision in recent years, and diagnostic criteria have been recently revised by the International Pediatric Multiple Sclerosis Study Group (IPMSSG) [6]. The paper “Pediatric multiple sclerosis: current concepts and consensus definitions” offers a careful update on risk factors, clinical manifestations, diagnostic procedures, prognostic implications, and treatment of this increasingly frequent form of MS. \u0000 \u0000MS is a salient neuroimmunological disease for which the “bench to bedside approach” has provided the greatest therapeutic advances. Although there are more treatments for MS, the study of novel and less explored molecular pathways ought to provide relevant alternative targets. This concept is well expressed in the paper entitled “Current understanding on the role of standard- and immuno-proteasomes in inflammatory/immunological pathways of Multiple Sclerosis,” in which the authors describe the current knowledge on the potential role of proteasomes in MS and discuss the pro et contra of possible therapies for MS targeting proteasome isoforms. \u0000 \u0000Immune mediated diseases of the peripheral nervous system (PNS) are less studied than their “central” counterparts [7]. Nonetheless, important advances in both pathogenesis and treatment of inflammatory demyelinating neuropathies have been extensively evaluated in the articles authored by J. B. Weiner and P. Ripellino et al. The first publication entitled “An update in Guillain-Barre Syndrome” provides a comprehensive discussion of the current state of knowledge on acute inflammatory neuropathies from diagnosis to treatment. The se","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"812847"},"PeriodicalIF":4.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/812847","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32158476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genes associated with SLE are targets of recent positive selection. 与系统性红斑狼疮相关的基因是近期正向选择的目标。
IF 1.7 Q4 IMMUNOLOGY Pub Date : 2014-01-01 Epub Date: 2014-01-23 DOI: 10.1155/2014/203435
Paula S Ramos, Stephanie R Shaftman, Ralph C Ward, Carl D Langefeld

The reasons for the ethnic disparities in the prevalence of systemic lupus erythematosus (SLE) and the relative high frequency of SLE risk alleles in the population are not fully understood. Population genetic factors such as natural selection alter allele frequencies over generations and may help explain the persistence of such common risk variants in the population and the differential risk of SLE. In order to better understand the genetic basis of SLE that might be due to natural selection, a total of 74 genomic regions with compelling evidence for association with SLE were tested for evidence of recent positive selection in the HapMap and HGDP populations, using population differentiation, allele frequency, and haplotype-based tests. Consistent signs of positive selection across different studies and statistical methods were observed at several SLE-associated loci, including PTPN22, TNFSF4, TET3-DGUOK, TNIP1, UHRF1BP1, BLK, and ITGAM genes. This study is the first to evaluate and report that several SLE-associated regions show signs of positive natural selection. These results provide corroborating evidence in support of recent positive selection as one mechanism underlying the elevated population frequency of SLE risk loci and supports future research that integrates signals of natural selection to help identify functional SLE risk alleles.

系统性红斑狼疮(SLE)的发病率存在种族差异,而人群中系统性红斑狼疮风险等位基因的频率相对较高,其原因尚不完全清楚。人口遗传因素(如自然选择)会改变等位基因的世代频率,这可能有助于解释这种常见风险变异在人口中的持续存在以及系统性红斑狼疮的不同风险。为了更好地了解可能由自然选择引起的系统性红斑狼疮的遗传基础,我们使用基于种群分化、等位基因频率和单倍型的测试方法,检测了 HapMap 和 HGDP 种群中与系统性红斑狼疮相关的 74 个基因组区域,以寻找近期正选择的证据。在几个与系统性红斑狼疮相关的基因座上,包括 PTPN22、TNFSF4、TET3-DGUOK、TNIP1、UHRF1BP1、BLK 和 ITGAM 基因,不同的研究和统计方法都观察到了一致的正选择迹象。这项研究首次评估并报告了多个系统性红斑狼疮相关区域显示出积极自然选择的迹象。这些结果提供了确凿的证据,证明近期的正向选择是导致系统性红斑狼疮风险基因位点群体频率升高的机制之一,并支持未来的研究将自然选择的信号整合起来,以帮助识别功能性系统性红斑狼疮风险等位基因。
{"title":"Genes associated with SLE are targets of recent positive selection.","authors":"Paula S Ramos, Stephanie R Shaftman, Ralph C Ward, Carl D Langefeld","doi":"10.1155/2014/203435","DOIUrl":"10.1155/2014/203435","url":null,"abstract":"<p><p>The reasons for the ethnic disparities in the prevalence of systemic lupus erythematosus (SLE) and the relative high frequency of SLE risk alleles in the population are not fully understood. Population genetic factors such as natural selection alter allele frequencies over generations and may help explain the persistence of such common risk variants in the population and the differential risk of SLE. In order to better understand the genetic basis of SLE that might be due to natural selection, a total of 74 genomic regions with compelling evidence for association with SLE were tested for evidence of recent positive selection in the HapMap and HGDP populations, using population differentiation, allele frequency, and haplotype-based tests. Consistent signs of positive selection across different studies and statistical methods were observed at several SLE-associated loci, including PTPN22, TNFSF4, TET3-DGUOK, TNIP1, UHRF1BP1, BLK, and ITGAM genes. This study is the first to evaluate and report that several SLE-associated regions show signs of positive natural selection. These results provide corroborating evidence in support of recent positive selection as one mechanism underlying the elevated population frequency of SLE risk loci and supports future research that integrates signals of natural selection to help identify functional SLE risk alleles. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"203435"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32170477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Autoimmune Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1